Tesamorelin and GH Pulsatility: Which Readouts Actually Changed?
Tesamorelin changed several growth-hormone secretion readouts in a small, short human study, but it did not simply “create more pulses.” After two weeks, mean overnight GH, average pulse area, basal secretion, and IGF-I increased. The number of secretion events was not reported as the main changed feature. Pulse size, pulse frequency, baseline secretion, and a downstream marker answer different questions.
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue. It belongs in a GHRH research framework rather than being treated as growth hormone itself. A useful starting point is the comparison of CJC-1295, Sermorelin, and Tesamorelin, which keeps the related analogue records separate.
What did the frequent-sampling study measure?
The key primary study enrolled 13 men and collected blood frequently overnight at baseline, after two weeks of tesamorelin, and again after withdrawal. Its prespecified primary endpoint was mean overnight GH. Secondary measures included pulse area, pulse frequency, basal GH secretion, total production, and IGF-I. According to the original clinical study, mean overnight GH, average log-transformed peak area, basal secretion, and IGF-I increased after the intervention.
These terms should not be collapsed into one label. Mean concentration summarizes the entire sampling window. Pulse area estimates the amount represented by a detected secretory event. Basal secretion estimates the nonpulsatile component between events. Pulse frequency counts detected events. IGF-I is a downstream endocrine measure with different kinetics.
| Readout | What it describes | What the cited study supports | What it does not establish |
|---|---|---|---|
| Mean overnight GH | Average concentration during frequent sampling | Increased after two weeks | Which secretion component caused every part of the increase |
| Peak or pulse area | Size of detected secretory events | Average peak area increased | A universal effect in every population or protocol |
| Basal secretion | Estimated secretion between pulses | Increased in the deconvolution analysis | That secretion was exclusively pulsatile |
| Pulse frequency | Number of detected events | It was measured | That frequency was the principal changed variable |
| IGF-I | Downstream response over a longer time scale | Increased over the two-week interval | A direct measurement of individual GH pulses |
Why mean GH and pulse frequency are different claims
Two concentration profiles can have the same number of peaks yet different mean values if the peaks are larger or the baseline between them is higher. Conversely, more detected events do not automatically mean a greater total output. Detection also depends on sampling interval, assay sensitivity, and the algorithm used to identify pulses.
A related analysis from the same research program found that adiponectin associations differed among GH secretion measures and that adiponectin was not associated with the number of secretion events. That secondary analysis reinforces a practical lesson: endocrine time-series variables are not interchangeable merely because they come from the same blood samples.
For broader terminology, the growth-hormone peptide guide explains why GHRH analogues, secretagogues, GH, and IGF-axis materials need separate names. Researchers reviewing Tesamorelin can also compare the exact material listing with the wider Growth Hormone Peptides collection without transferring results from another analogue.
How to read a pulsatility claim
Start with the sampling design. A single blood draw cannot describe a pulse pattern. Frequent sampling over a defined window is needed, and overnight results should not be assumed to represent every time of day. Next, identify whether the paper reports observed concentrations, modeled secretion, or both. Modeled basal secretion and pulse mass depend on the analysis method.
Then separate the endpoints. “Higher mean GH” is not a substitute for “more frequent pulses.” “Higher IGF-I” is not a pulse measurement. Finally, preserve the study population and duration. A two-week study in 13 men is informative for the measured variables, but it is not a general proof for other populations, time frames, materials, or outcomes.
The CJC-1295 DAC and no-DAC record guide shows the same source-matching principle from a different angle: modification, exposure design, and sampling schedule affect what a study can answer. The NEXTWAVE PEPTIDES catalog and COA library can document a listed research material, while the cited paper documents its own intervention and protocol. Those are complementary records, not substitutes.
Research limitations
The primary pulsatility study was small, short, and conducted in a specific group of men. It used a defined intervention and frequent overnight sampling with deconvolution analysis. The results do not validate an untested lot, establish long-term outcomes, or show that every GH-related peptide changes the same variables. The article describes research evidence and analytical interpretation; it does not provide instructions for human use.
Frequently asked questions
Did tesamorelin increase the number of GH pulses?
The study measured pulse frequency, but its clear reported increases were mean overnight GH, average pulse area, basal secretion, and IGF-I. It is more accurate to name those changed readouts than to summarize the result as “more pulses.”
Is IGF-I the same as a GH pulse measurement?
No. IGF-I is a downstream endocrine marker measured on a different time scale. It can support evidence of axis response, but it does not reveal the timing or size of individual GH secretory events.
Can a single GH result describe pulsatility?
No. Pulsatility requires repeated measurements across time plus a defined method for identifying or modeling secretory events.
Does this evidence apply to other GHRH analogues?
Not automatically. Each analogue, modification, exposure schedule, population, and assay design needs its own evidence record.